Reducing cannabis use for sleep among adults using medical cannabis

项目总结/摘要 近年来，推动医用大麻合法化的运动在美国日益壮大 现在29个州和哥伦比亚特区都有允许将大麻用于医疗用途的规定。 原因无论寻求医用大麻的具体原因如何，接受过评估的成年人 医用大麻认证报告了严重的睡眠相关问题以及频繁使用大麻， 解决他们的睡眠问题大麻用于睡眠是一个关键的潜在干预目标， 研究发现，在患有大麻使用障碍的人中，睡眠不足是持续使用大麻的障碍。 大麻使用的缓解。失眠的认知行为疗法（CBT）对个人非常有效 失眠与其他健康状况共病，包括物质使用障碍;然而， 疗效试验没有具体评估其对使用大麻治疗失眠的人的益处。的影响 因此，在医用大麻使用者中使用CBT治疗失眠或使用大麻是未知的。的 该项目的目标是调整和定制一个电话提供的CBT失眠的成年人谁使用 医用大麻（CBTi-CB），并评估这种干预的可接受性和可行性。定性 将收集定量数据，以完善现有的CBTi-CB协议，并对 对使用医用大麻的成年人进行改良干预。寻求医用大麻认证的成年人将 在等待预约的时候，他们会被接触，并接受失眠和大麻使用的筛查， 睡吧在初步定性访谈和beta测试后，合格的参与者（N = 40）将被随机分配至 CBTi-CB或睡眠教育控制（SE）条件，通过电话提供。参与者将提供自我- 将报告有关睡眠/失眠、功能和大麻使用的数据以及有关睡眠质量的客观数据， 通过腕动记录仪测量。这项研究将评估自我报告和客观测量的睡眠变化， 在治疗期间和治疗后18周内使用大麻的功能和频率/数量 基线。研究目标的完成将为未来的全动力 CBTi-CB在医用大麻使用者中的长期疗效的随机试验。这行 这项研究将是第一个评估高效的睡眠干预措施并确定其效果的研究。 在非寻求治疗的人群中使用与睡眠有关和与睡眠无关的大麻。

Project Summary/Abstract In recent years, the movement to promote the legalization of medical cannabis has grown in the United States and now 29 States and the District of Columbia have provisions that allow for the use of cannabis for medical reasons. Irrespective of the specific reasons for seeking medical cannabis, adults who have been evaluated for medical cannabis certification report significant sleep-related problems as well as frequent use of cannabis to address their sleep problems. Cannabis use for sleep is a key potential target for interventions given that prior research has found that, among individuals with cannabis use disorders, poor sleep is a barrier to sustained remission from cannabis use. Cognitive Behavioral Therapy (CBT) for insomnia is highly effective in individuals with insomnia comorbid with other health conditions, including substance use disorders; however, existing efficacy trials have not specifically evaluated its benefit in those who use cannabis for insomnia. The impact of CBT for insomnia on either sleep or cannabis use in medical cannabis users is, therefore, unknown. The objectives of this project are to adapt and tailor a telephone-delivered CBT for insomnia for adults who use medical cannabis (CBTi-CB) and to evaluate the acceptability and feasibility of this intervention. Qualitative and quantitative data will be collected to refine an existing CBTi-CB protocol and conduct a pilot test of the modified intervention in adults who use medical cannabis. Adults seeking certification for medical cannabis will be approached while waiting for their appointment and screened for insomnia as well as cannabis use for sleep. After initial qualitative interviews and beta testing, eligible participants (N = 40) will be randomized to CBTi-CB or Sleep Education Control (SE) condition, delivered over the telephone. Participants will provide self- report data on sleep/insomnia, functioning and cannabis use and objective data on sleep quality will be measured by actigraphy. The study will evaluate changes in self-reported and objectively measured sleep, functioning and frequency/quantity of cannabis use during treatment and over the course of 18-weeks post- baseline. Completion of the study aims will provide all of the elements required for a future fully-powered randomized trial of the longer-term efficacy of CBTi-CB among those with medical cannabis. This line of research would be the first to evaluate a highly effective sleep-focused intervention and determine the effects on sleep-related and non-sleep-related cannabis use in a non-treatment seeking population.